Regulation of ryanodine receptors by dopamine D1 receptors during methamphetamine-induced place conditioning.
Little is known about ryanodine receptors (RyRs) related to the methamphetamine (METH)-induced place preference. The present study was designed to ascertain whether RyRs could play a role in the development of METH-induced place preference in the mouse. The METH-induced place preference was dose-dependently suppressed by dantrolene, a RyRs receptor antagonist. The levels of RyRs 1 and 2 in the frontal cortex and RyRs 1 in the limbic forebrain were significantly increased in METH-conditioned mice. This up-regulation of RyRs were not inhibited by nifedipine. Both the dopamine D(1) receptor antagonist SCH23390 and the dopamine D(2) receptor antagonist sulpiride inhibited the development of METH-induced place conditioning. In contrast, the increases of RyRs 1 and 2 in the frontal cortex and of RyRs 1 in the limbic forebrain were completely abolished by SCH23390, whereas sulpiride had no effect. These findings indicate that up-regulation of RyRs is regulated through the activation of dopamine D(1) receptors in the METH-conditioning.
Kurokawa
Kazuhiro
K
Department of Pharmacology, Kawasaki Medical School, Matsushima, Kurashiki, Japan.
Mizuno
Koji
K
Shibasaki
Masahiro
M
Ohkuma
Seitaro
S
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003213:Conditioning, Psychological / Q000187:drug effects*; D003620:Dantrolene / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D007276:Injections, Intraventricular / Q000379:methods; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D009125:Muscle Relaxants, Central / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D019837:Ryanodine Receptor Calcium Release Channel / Q000145:classification / Q000235:genetics / Q000378:metabolism*; D013469:Sulpiride / Q000494:pharmacology
D001552:Benzazepines; C485995:Cacna1d protein, mouse; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D000697:Central Nervous System Stimulants; D018492:Dopamine Antagonists; C419385:L-type calcium channel alpha(1C); D009125:Muscle Relaxants, Central; D017447:Receptors, Dopamine D1; D019837:Ryanodine Receptor Calcium Release Channel; C534628:SCH 23390; D008694:Methamphetamine; D013469:Sulpiride; D003620:Dantrolene; D009543:Nifedipine